A clinical dilemma; single prostatic cancer focus in biopsy. Interpretation and management

Journal of B.U.ON.

Volumn 15, Issue 1, 2010, Pages 19-24

  Efthimiou, I ^a   Skrepetis, K ^b   Bournia, E ^b  

^a General Hospital of Chios   (Greece)

^b Kalamata General Hospital   (Greece)

Author keywords

Biopsy; Minimal cancer; Prostate cancer

Indexed keywords

CANCER SCREENING; CANCER SIZE; EARLY DIAGNOSIS; ECHOGRAPHY; FALSE POSITIVE RESULT; HUMAN; NEEDLE BIOPSY; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT;

BIOPSY, NEEDLE; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 77950975363     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57: 43-46.
2. Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994; 152: 1753-1756. (Pubitemid 24322622)
3. Chodak GW, Thisted RA, Gerber GS et al. Results of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-242
4. Weldon VE, Tavel FR, Neuwirth H, Cohen R. Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J Urol 1995; 154: 1074-1077.
5. Zackisson B, Aus G, Bergdahl et al. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol 2004; 1714: 1500-1503.
6. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003; 170: 370-372. (Pubitemid 36870202)
7. Boccon-Gibod LM, Toublanc O, Ravery V, Boccon-Gibod LA. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005; 48: 895-899. (Pubitemid 41641631)
8. Van der Kwast T, Wolters T, Evans A, Roobol M. Single prostate cancer foci on prostate biopsy. Eur Urol Suppl 2008; 7: 549-556.
9. Thorson P, Arcangeli C, Keetch DW. Diagnostic features and follow-up of minimal carcinoma in prostate needle biopsies. Mod Pathol 1998; 11: 543-551.
10. Leroy X, Aubert S, Villers A et al. Minimal focus of adenocarcinoma on prostate biopsy: clinicopathological correlations. J Clin Pathol 2003; 56: 230-232. (Pubitemid 36308041)
11. Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate cancer biopsy tissue. Ann Pathol 2000; 114: 896-909. (Pubitemid 33051890)
12. Algaba F, Epstein J, Aldape et al. Assessment of prostate carcinoma in core needle biopsy-definition of minimal criteria for diagnosis of cancer in biopsy material. Cancer 1996; 78: 376-381. (Pubitemid 26236279)
13. Thorson P, Vollmer RT, Arcangeli C et al. Minimal adenocarcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol 1998; 11: 543-551. (Pubitemid 28280718)
14. Cheville JC, Reznicek MJ, Bostwick DC. The focus of "atypal glands, suspicious for malignancy" in prostate needle biopsy. Am J Clin Pathol 1997; 108: 633-690
15. Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma. Arch Pathol Lab Med 2000; 124: 98-107.
16. Iczkowski KA. Current prostate biopsy interpretation: Criteria for cancer, atypical small acinar proliferation, high grade prostatic intraepithelial neoplasia and use of immunostains. Arch Pathol Lab Med 2006; 130: 835-842.
17. Wojno KL, Epstein JI. The utility of basal cell specific anticytokeratin antibody (34 beta E12) in the diagnosis of prostate carcinoma: a review of 228 cases. Am J Surg Pathol 1995; 19: 251-260.
18. Epstain JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 2004; 17: 307-315.
19. Garcia FU, Haber MM, Chen X. Prostatic basal cells in the peripheral and transitional zones: zonal variation in morphology and in immunophenotype. Prostate 2007; 67: 1686-1692. (Pubitemid 350036954)
20. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol 2007; 60: 35-42.
21. Postma R, de Vries SH, Roobol MJ et al. Incidence and follow up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 2005; 103: 708-716. (Pubitemid 40216398)
22. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. The utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005; 66: 356-360. (Pubitemid 41138097)
23. Egevad L, Norberg M, Mattson S, Norlen BJ, Busch C. Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy. Urology 1998; 52: 653-658. (Pubitemid 28440175)
24. Ochiai A, Tripkov K, Yilmaz A et al. Validation of a prediction model for low volume/low grade cancer application in selecting patients for active surveillance. J Urol 2007; 177: 907-910. (Pubitemid 46216359)
25. Skrepetis K, Doumas K, Lykourinas M. Discrepancy between Gleason score of biopsy and radical prostatectomy specimens. Eur Urol 2001; 40: 238. (Pubitemid 32786113)
26. Yang XJ, Lecksell K, Potter SR et al. Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy. Urology 1999; 54: 528-532. (Pubitemid 29407033)
27. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664-1669. (Pubitemid 34240696)
28. Van de Berg RC, Reomeling S, Roobol MJ et al. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007; 52: 1560-1563. (Pubitemid 350052404)
29. Boccon-Gobod LM, de Longchamps NB, Toublanc M et al. Prostate saturation biopsy in the re-evaluation of microfocal prostate cancer. J Urol 2006; 176: 961-964. (Pubitemid 44142560)
30. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Eng J Med 2004; 351: 125-135.
31. Clinical practice guidelines in oncology. Prostate cancer v.2.2007. National Comprehensive Cancer Network Wed site. http:www.nccn.org.